Canaccord Genuity Rates Bioventus (BVS) buy, $15 Price Target
Canaccord Genuity maintains its Buy rating on BVS, setting a price target of $15, a 74.42% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Canaccord Genuity rated Bioventus Inc. ($BVS) "buy" with a $15 price target on June 16, 2026.
Since the rating, $BVS is up 6.5% after 1 week, up 42.5% after 1 month and up 52.5% to date (from the $8.72 close on Jun 16, 2026).
BVS
Bioventus Inc.
Key Points
- Canaccord Genuity reiterated its Buy rating for BVS with a price target of $15 on June 16, 2026.
- Canaccord Genuity's $15 price target implies 74.42% upside from Bioventus Inc.'s ($BVS) current $8.60 share price.
- BVS shares are trading at $8.60, reflecting analyst confidence despite market fluctuations.
- Institutional investors like Nantahala Capital Management and BlackRock have adjusted their holdings in BVS recently.
Get $BVS trade alerts by text
We text you when insiders, Congress or big funds trade $BVS. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Bioventus Inc. alert may contain errors. Disclosures
Canaccord Genuity has reiterated its Buy rating on BVS, setting a price target of $15. This reaffirmation came on June 16, 2026, as analyst Caitlin Cronin expressed confidence in the company's prospects. BVS shares are currently trading at $8.60.
Other Institutional Activity in BVS
Several institutional investors have been active in BVS recently. Nantahala Capital Management increased its holdings by 75,000 shares, bringing its total to 6,122,403 shares valued at approximately $55.9 million. BlackRock, Inc. added 9,357 shares, ending with 3,133,541 shares worth about $28.6 million. Meanwhile, Royce & Associates LP made a more significant move, adding 290,000 shares to reach a total of 1,541,282 shares, valued around $14.1 million.
Insider Buying and Selling at Bioventus Inc.
On June 3, 2026, several insiders at BVS made notable purchases. Philip Cowdy, Mary Kay Ladone, Pat Beyer, Martin Sutter, and Guido Neels each bought 25,146 shares. William Hawkins also acquired 30,994 shares. These transactions were not part of any pre-arranged trading plans.
Analysts Set New Price Targets
On June 16, 2026, Canaccord Genuity maintained its Buy rating on BVS with a $15 price target. Previously, Barrington Research also maintained a Buy rating with a $14 target on May 22, 2026. Craig-Hallum kept its Buy rating with a $16 target on March 6, 2026. The consensus among analysts remains optimistic, with a strong Buy recommendation and a mean target price reflecting positive expectations for BVS.
Bottom Line
Canaccord Genuity's reaffirmation of its Buy rating and a $15 target demonstrates continued confidence in BVS's potential. Institutional investors have made various adjustments to their holdings, indicating active interest in the stock. Insider purchases further suggest confidence among company executives. As always, it's important for investors to remember that these analyses reflect past actions and may not indicate future performance.
$BVS price target
Bioventus Inc. daily closes and this analyst's $15 target. Not advice.
Related Filing Alerts
Source: Canaccord Genuity's rating change on $BVS (Jun 16, 2026). Written by software, not financial advice. How we make alerts